# Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

> **NCT04662788** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** NK cells/Combined Monoclonal Antibodies

## Key facts

- **NCT ID:** NCT04662788
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662788, "Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04662788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*